Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.651 USD -0.02 ( 1.43%)
Last update at 2026-11-06T21:00:00Z
VOLUME
18807
Market Cap
5.92M

Momentum Score

…

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.60
Low
1.71
High
52 Week Price Range
0.97
Low
7.91
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cardio Diagnostics Holdings Inc is a small-cap medical company that, per public filings, develops cardiovascular diagnostic tests and services for earlier detection and monitoring of heart disease. Long-term growth drivers may include ageing populations, rising cardiovascular disease prevalence and wider adoption and reimbursement of non-invasive diagnostics. Investors may find the company attractive for potential revenue leverage if its tests gain clinical adoption and payer coverage.

Principal risks are limited public disclosure, a small operational and financial base, execution and commercialization challenges, regulatory and reimbursement uncertainty, and likely need for external financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.68
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
0.01
Gross Profit TTM
0.01M
Debt / Equity
0.10
ROE
-75.44%
Net Debt
-4.42M
ROCE
-90.54%
Diluted EPS TTM
-2.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.50M -8.38M -8.38M -4.66M -0.62M
Net income -6.50M -8.38M -8.38M -4.66M -0.62M
Selling general administrative 5.79M 8.17M 6.94M 4.40M 0.47M
Selling and marketing expenses 0.77M 0.18M 0.16M 0.09M 0.10M
Gross profit -0.38M 0.03M 0.02M 0.00M 0.00M
Reconciled depreciation 0.40M 0.28M 0.05M 0.02M 0.02M
Ebit -6.48M -8.36M -1.64M -4.44M -0.62M
Ebitda -6.09M -8.09M -1.53M -4.42M -0.60M
Depreciation and amortization 0.40M 0.28M 0.11M 0.02M 0.02M
Operating income -6.48M -8.37M -7.24M -4.55M -0.62M
Other operating expenses 6.50M 8.40M 7.26M 4.55M 0.62M
Interest expense 0.01M 0.02M 6.74M - -
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.00M 0.00M 0.00M - -
Net interest income -0.01M -0.02M -6.73M - -
Income tax expense - - - 0.11M -
Total revenue 0.01M 0.03M 0.02M 0.00M 0.00M
Total operating expenses 6.10M 8.40M 7.26M 4.55M 0.62M
Cost of revenue 0.40M 0.28M 0.11M - -
Total other income expense net -0.01M -0.02M -1.13M -0.11M -
Net income from continuing ops -6.50M -8.38M -9.37M -4.66M -0.62M
Net income applicable to common shares - - - - -0.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.77M 10.62M 4.46M 6.25M 1.10M
Intangible assets 0.87M 0.71M 0.54M 0.36M 0.30M
Other current assets 0.80M 0.94M 1.22M 1.77M 0.04M
Total liab 0.79M 1.06M 1.50M 1.95M 0.03M
Total stockholder equity 6.97M 9.56M 2.96M 4.30M 1.07M
Other current liab - 0.54M 0.22M - -
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -29.25M -22.75M -14.37M -5.99M -1.33M
Good will - 0.70M - - -
Cash 5.11M 7.83M 1.28M 4.12M 0.51M
Total current liabilities 0.60M 0.63M 0.84M 0.85M 0.03M
Current deferred revenue - - -0.22M - -
Net debt -4.42M -6.86M -0.02M -4.12M -0.51M
Short term debt 0.51M 0.54M 0.60M - -
Short long term debt 0.27M 0.31M - - -
Short long term debt total 0.70M 0.97M 1.26M - -
Other stockholder equity 36.22M 32.31M 17.33M 10.29M 2.40M
Total current assets 5.92M 8.79M 2.77M 5.89M 0.80M
Net tangible assets - - - - 0.77M
Net receivables 0.01M 0.02M 0.26M 0.00M 0.00M
Inventory - - - - 0.25M
Accounts payable 0.10M 0.09M 0.24M 1.10M 0.03M
Accumulated other comprehensive income - 0.00M 0.00M - -
Non currrent assets other 0.01M 0.01M 0.01M 0.00M -
Non current assets total 1.85M 1.82M 1.70M 0.36M 0.30M
Capital lease obligations 0.43M 0.66M 0.89M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.40M -0.23M -0.37M -0.36M
Change to liabilities - - - - -0.01M
Total cashflows from investing activities -0.42M -0.40M -0.79M - -0.36M
Net borrowings - 0.00M 4.50M - -
Total cash from financing activities 3.43M 11.94M 3.63M 9.06M 1.23M
Change to operating activities - - - - -0.03M
Net income -6.50M -8.38M -8.38M -4.66M -0.62M
Change in cash -2.72M 6.54M -2.83M 3.60M 0.28M
Begin period cash flow 7.83M 1.28M 4.12M 0.51M 0.24M
End period cash flow 5.11M 7.83M 1.28M 4.12M 0.51M
Total cash from operating activities -5.73M -4.99M -5.67M -5.09M -0.59M
Issuance of capital stock 3.80M 12.55M 0.00M 11.99M 1.12M
Depreciation 0.16M 0.28M 0.11M 0.02M 0.02M
Other cashflows from investing activities -0.23M -0.19M -0.20M - -0.25M
Change to inventory - - 0.00M - -
Change to account receivables 0.01M -0.01M -0.00M 0.00M -0.00M
Other cashflows from financing activities 3.43M -0.61M -0.87M -2.92M 0.10M
Change to netincome - - - - 0.06M
Capital expenditures 0.19M 0.40M 0.79M 0.08M 0.11M
Change in working capital 0.26M 0.52M 0.21M -0.56M -0.04M
Stock based compensation 0.11M 2.59M 1.28M 0.00M 0.06M
Other non cash items 0.24M 0.00M 1.10M 0.11M -0.00M
Free cash flow -5.91M -5.40M -6.47M -5.17M -0.70M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CDIO
Cardio Diagnostics Holdings Inc		 -0.02
1.43%		 1.65 - - 409.62 0.82 62.91 -22.48
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

311 West Superior Street, Chicago, IL, United States, 60654

855 226 9991

https://cdio.ai

15

Name Title Year Born
Dr. Meeshanthini Dogan Ph.D. Co-Founder, CEO & Director 1989
Dr. Robert A. Philibert M.D., Ph.D. Co-Founder, Chief Medical Officer & Director 1962
Ms. Elisa Michael Luqman J.D., M.B.A. CFO & Director 1964
Mr. Timur Dogan Ph.D. Chief Technology Officer 1988
Ms. Khullani Abdullah J.D. VP of Revenue & Strategy 1983
Dr. Meeshanthini V. Dogan Ph.D. Co-Founder, CEO & Director 1989
Ms. Elisa Michael Luqman Esq., J.D., M.B.A. Chief Financial Officer 1964
Ms. Khullani Abdullahi J.D. Vice President of Revenue & Strategy 1984
Ms. Elisa Michael Luqman Esq., J.D., M.B.A. CFO & Principal Accounting Officer 1964
Mr. Timur Dogan Ph.D. Chief Technology Officer 1989

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…